Switch theme
Sign up to access all valuation multiples
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program’s drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib’s potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.
2017
106
Last FY Revenue n/a
LTM EBITDA -$133M
$26.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Biomea Fusion has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$133M.
In the most recent fiscal year, Biomea Fusion achieved revenue of n/a and an EBITDA of -$142M.
Biomea Fusion expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Biomea Fusion valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$133M | XXX | -$142M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$123M | XXX | -$144M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$119M | XXX | -$138M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Biomea Fusion's stock price is $1.
Biomea Fusion has current market cap of $54.1M, and EV of $26.2M.
See Biomea Fusion trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $26.2M | $54.1M | XXX | XXX | XXX | XXX | $-3.04 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Biomea Fusion has market cap of $54.1M and EV of $26.2M.
Biomea Fusion's trades at n/a EV/Revenue multiple, and -0.2x EV/EBITDA.
Equity research analysts estimate Biomea Fusion's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biomea Fusion has a P/E ratio of -0.5x.
See valuation multiples for Biomea Fusion and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $54.1M | XXX | $54.1M | XXX | XXX | XXX |
| EV (current) | $26.2M | XXX | $26.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/EBIT | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | -0.2x | XXX | -0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBiomea Fusion's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.4M for the same period.
Biomea Fusion's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Biomea Fusion's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Biomea Fusion and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | -11% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biomea Fusion acquired XXX companies to date.
Last acquisition by Biomea Fusion was XXXXXXXX, XXXXX XXXXX XXXXXX . Biomea Fusion acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Biomea Fusion founded? | Biomea Fusion was founded in 2017. |
| Where is Biomea Fusion headquartered? | Biomea Fusion is headquartered in United States of America. |
| How many employees does Biomea Fusion have? | As of today, Biomea Fusion has 106 employees. |
| Who is the CEO of Biomea Fusion? | Biomea Fusion's CEO is Dr. Michael J. M. Hitchcock, PhD. |
| Is Biomea Fusion publicy listed? | Yes, Biomea Fusion is a public company listed on NAS. |
| What is the stock symbol of Biomea Fusion? | Biomea Fusion trades under BMEA ticker. |
| When did Biomea Fusion go public? | Biomea Fusion went public in 2021. |
| Who are competitors of Biomea Fusion? | Similar companies to Biomea Fusion include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Biomea Fusion? | Biomea Fusion's current market cap is $54.1M |
| Is Biomea Fusion profitable? | Yes, Biomea Fusion is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Biomea Fusion? | Biomea Fusion's last 12 months EBITDA is -$133M. |
| What is the current EV/EBITDA multiple of Biomea Fusion? | Current EBITDA multiple of Biomea Fusion is -0.2x. |
| What is the current FCF of Biomea Fusion? | Biomea Fusion's last 12 months FCF is -$121M. |
| What is the current EV/FCF multiple of Biomea Fusion? | Current FCF multiple of Biomea Fusion is -0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
